Chemo Research SL

General

Total Cases9

Active Cases4

Patents4

CourtsD. Delaware D. New Jersey

TypeOperating Company

Elite Ratings

--

Ratings

Experience

Grade

Trend

DCT

--

--

--

PTAB

--

--

--

CAFC

--

--

--

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered	Case	Description
09/12/24	Exeltis USA Inc v. Lupin Ltd 1:22-CV-00434 ( D. DE )	NOTICE requesting Clerk to remove Michael K. Nutter, Merritt Westcott, Corinne S. Hockman and Daniel P. Withers as co-counsel. Reason for request: no longer affiliated with the case. (Bilson, David) (Entered: 09/12/2024)
09/12/24	Exeltis USA Inc v. Lupin Ltd 1:22-CV-00434 ( D. DE )	NOTICE requesting Clerk to remove Michael K. Nutter, Merritt Westcott, Corinne S. Hockman and Daniel P. Withers as co-counsel. Reason for request: no longer affiliated with the case. (Bilson, David) (Entered: 09/12/2024)
09/11/24	Exeltis USA Inc v. Lupin Ltd 1:22-CV-00434 ( D. DE )	Joint letter to The Honorable Richard G. Andrews, from Jonathan A. Bell, regarding proposed final judgment. (Attachments: # [1] Exhibit 1, # [2] Exhibit 2)(Bell, Jon) Modified on 9/12/2024 (nms). (Entered: 09/11/2024)
09/11/24	Exeltis USA Inc v. Lupin Ltd 1:22-CV-00434 ( D. DE )	Joint letter to The Honorable Richard G. Andrews, from Jonathan A. Bell, regarding proposed final judgment. (Attachments: # [1] Exhibit 1, # [2] Exhibit 2)(Bell, Jon) Modified on 9/12/2024 (nms). (Entered: 09/11/2024)
09/04/24	Exeltis USA Inc v. Lupin Ltd 1:22-CV-00434 ( D. DE )	TRIAL OPINION: For the foregoing reasons, I find that Exeltis has proven by a preponderance of the evidence that Lupin infringes claim 14 of the '299 patent, claims 12 and 21 of the '632 patent, claim 29 of the '122 patent, claim 7 of the '249 patent, and claim 19 of the '487 patent. Lupin has failed to prove by clear and convincing evidence that the asserted claims are indefinite. Lupin has also failed to prove by clear and convincing evidence that claim 29 of the '122 patent and claim 7 of the '249 patent are invalid for lack of written description. Lastly, Lupin has failed to prove by clear and convincing evidence that the six asserted claims are invalid as obvious. Exeltiss evidence regarding objective indicia supports a finding of nonobviousness. The parties shall submit a final judgment consistent with this memorandum opinion within one week. Signed by Judge Richard G. Andrews on 9/4/2024. (nms) (Entered: 09/04/2024) TRIAL OPINION: For the foregoing reasons, I find that Exeltis has proven by a preponderance of the evidence that Lupin infringes claim 14 of the '299 patent, claims 12 and 21 of the '632 patent, claim 29 of the '122 patent, claim 7 of the '249 patent, and claim 19 of the '487 patent. Lupin has failed to prove by clear and convincing evidence that the asserted claims are indefinite. Lupin has also failed to prove by clear and convincing evidence that claim 29 of the '122 patent and claim 7 of the '249 patent are invalid for lack of written description. Lastly, Lupin has failed to prove by clear and convincing evidence that the six asserted claims are invalid as obvious. Exeltiss evidence regarding objective indicia supports a finding of nonobviousness. The parties shall submit a final judgment consistent with this memorandum opinion within one week. Signed by Judge Richard G. Andrews on 9/4/2024. (nms) (Entered: 09/04/2024)
09/04/24	Exeltis USA Inc v. Lupin Ltd 1:22-CV-00434 ( D. DE )	TRIAL OPINION: For the foregoing reasons, I find that Exeltis has proven by a preponderance of the evidence that Lupin infringes claim 14 of the '299 patent, claims 12 and 21 of the '632 patent, claim 29 of the '122 patent, claim 7 of the '249 patent, and claim 19 of the '487 patent. Lupin has failed to prove by clear and convincing evidence that the asserted claims are indefinite. Lupin has also failed to prove by clear and convincing evidence that claim 29 of the '122 patent and claim 7 of the '249 patent are invalid for lack of written description. Lastly, Lupin has failed to prove by clear and convincing evidence that the six asserted claims are invalid as obvious. Exeltiss evidence regarding objective indicia supports a finding of nonobviousness. The parties shall submit a final judgment consistent with this memorandum opinion within one week. Signed by Judge Richard G. Andrews on 9/4/2024. (nms) (Entered: 09/04/2024) TRIAL OPINION: For the foregoing reasons, I find that Exeltis has proven by a preponderance of the evidence that Lupin infringes claim 14 of the '299 patent, claims 12 and 21 of the '632 patent, claim 29 of the '122 patent, claim 7 of the '249 patent, and claim 19 of the '487 patent. Lupin has failed to prove by clear and convincing evidence that the asserted claims are indefinite. Lupin has also failed to prove by clear and convincing evidence that claim 29 of the '122 patent and claim 7 of the '249 patent are invalid for lack of written description. Lastly, Lupin has failed to prove by clear and convincing evidence that the six asserted claims are invalid as obvious. Exeltiss evidence regarding objective indicia supports a finding of nonobviousness. The parties shall submit a final judgment consistent with this memorandum opinion within one week. Signed by Judge Richard G. Andrews on 9/4/2024. (nms) (Entered: 09/04/2024)
08/28/24	Exeltis USA Inc v. Lupin Ltd 1:22-CV-00434 ( D. DE )	REDACTED VERSION of [365] Declaration of Brian Segers, by Chemo Iberica, S.A., Chemo Research, S.L., Exeltis USA, Inc., Laboratorios Leon Farma, S.A.. (Attachments: # [1] Exhibit 1, # [2] Exhibit 2, # [3] Exhibit 3, # [4] Exhibit 4, # [5] Exhibit 5, # [6] Exhibit 6, # [7] Exhibit 7, # [8] Exhibit 8, # [9] Exhibit 9, # [10] Exhibit 10, # [11] Exhibit 11, # [12] Exhibit 12, # [13] Exhibit 13, # [14] Exhibit 14, # [15] Exhibit 15, # [16] Exhibit 16, # [17] Exhibit 17, # [18] Exhibit 18)(Bell, Jon) Modified on 8/29/2024 (nms). (Entered: 08/28/2024) REDACTED VERSION of [365] Declaration of Brian Segers, by Chemo Iberica, S.A., Chemo Research, S.L., Exeltis USA, Inc., Laboratorios Leon Farma, S.A.. (Attachments: # [1] Exhibit 1, # [2] Exhibit 2, # [3] Exhibit 3, # [4] Exhibit 4, # [5] Exhibit 5, # [6] Exhibit 6, # [7] Exhibit 7, # [8] Exhibit 8, # [9] Exhibit 9, # [10] Exhibit 10, # [11] Exhibit 11, # [12] Exhibit 12, # [13] Exhibit 13, # [14] Exhibit 14, # [15] Exhibit 15, # [16] Exhibit 16, # [17] Exhibit 17, # [18] Exhibit 18)(Bell, Jon) Modified on 8/29/2024 (nms). (Entered: 08/28/2024)
08/28/24	Exeltis USA Inc v. Lupin Ltd 1:22-CV-00434 ( D. DE )	REDACTED VERSION of [365] Declaration of Brian Segers, by Chemo Iberica, S.A., Chemo Research, S.L., Exeltis USA, Inc., Laboratorios Leon Farma, S.A.. (Attachments: # [1] Exhibit 1, # [2] Exhibit 2, # [3] Exhibit 3, # [4] Exhibit 4, # [5] Exhibit 5, # [6] Exhibit 6, # [7] Exhibit 7, # [8] Exhibit 8, # [9] Exhibit 9, # [10] Exhibit 10, # [11] Exhibit 11, # [12] Exhibit 12, # [13] Exhibit 13, # [14] Exhibit 14, # [15] Exhibit 15, # [16] Exhibit 16, # [17] Exhibit 17, # [18] Exhibit 18)(Bell, Jon) Modified on 8/29/2024 (nms). (Entered: 08/28/2024) REDACTED VERSION of [365] Declaration of Brian Segers, by Chemo Iberica, S.A., Chemo Research, S.L., Exeltis USA, Inc., Laboratorios Leon Farma, S.A.. (Attachments: # [1] Exhibit 1, # [2] Exhibit 2, # [3] Exhibit 3, # [4] Exhibit 4, # [5] Exhibit 5, # [6] Exhibit 6, # [7] Exhibit 7, # [8] Exhibit 8, # [9] Exhibit 9, # [10] Exhibit 10, # [11] Exhibit 11, # [12] Exhibit 12, # [13] Exhibit 13, # [14] Exhibit 14, # [15] Exhibit 15, # [16] Exhibit 16, # [17] Exhibit 17, # [18] Exhibit 18)(Bell, Jon) Modified on 8/29/2024 (nms). (Entered: 08/28/2024)
08/28/24	Exeltis USA Inc v. Lupin Ltd 1:22-CV-00434 ( D. DE )	REDACTED VERSION of [364] Declaration of Salustiano Perez, by Chemo Iberica, S.A., Chemo Research, S.L., Exeltis USA, Inc., Laboratorios Leon Farma, S.A.. (Attachments: # [1] Exhibit 1, # [2] Exhibit 2, # [3] Exhibit 3, # [4] Exhibit 4)(Bell, Jon) Modified on 8/29/2024 (nms). (Entered: 08/28/2024)
08/28/24	Exeltis USA Inc v. Lupin Ltd 1:22-CV-00434 ( D. DE )	REDACTED VERSION of [364] Declaration of Salustiano Perez, by Chemo Iberica, S.A., Chemo Research, S.L., Exeltis USA, Inc., Laboratorios Leon Farma, S.A.. (Attachments: # [1] Exhibit 1, # [2] Exhibit 2, # [3] Exhibit 3, # [4] Exhibit 4)(Bell, Jon) Modified on 8/29/2024 (nms). (Entered: 08/28/2024)